Reversal In CAR-T Patent Battle Shows Federal Circuit’s Preference For Narrow Claims
Executive Summary
Appeals court finds that Juno/BMS patent is invalid, overturning $1.2bn jury verdict against Kite/Gilead. Ruling illustrates court does not like functionally-defined patent claims, attorneys say. Decision could impact future CAR-T patents and disputes.
You may also be interested in...
New Data Brings Yescarta Closer To Blockbuster Territory
Gilead announced positive topline results from the ZUMA-7 trial of Yescarta in second-line large B-cell lymphoma, where the CAR-T would eventually compete with BMS’s Breyanzi and Novartis’ Kymriah.
Regeneron/Sanofi, Amgen PCSK9 Rivalry Continues, But Not In US Courts
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Gilead Avoids $2.5bn Jury Verdict As Judge Rules Merck's Hep C Patent Is Invalid
Merck to appeal decision after district court says Gilead's discovery of sofosbuvir was 'neither routine nor simple.'